Telix Pharmaceuticals Ltd ADR Financials
Telix Pharmaceuticals Ltd ADR (TLX) reported $803.8M in revenue for fiscal year 2025, up 55.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Rapid revenue growth has shifted into a cash-consuming expansion phase, with FY2025 relying more on prior liquidity than current operations.
FY2024's$416.8M financing inflow built a cash cushion that fell from$440.0M to$141.9M in FY2025 while operating cash flow swung from$27.5M to-$17.3M and investing outflow reached$285.9M . That combination shows a move from raising capital to consuming capital to expand, so the FY2025 revenue step-up was not yet self-funding.
Liquidity remains positive, but the current ratio compression from 2.8x to 1.4x matters because cash fell even as receivables and inventory increased, meaning more of each sales dollar was tied up in day-to-day operations instead of staying available as buffer.
Earnings quality and cash told the same story in FY2025: net margin moved from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Telix Pharmaceuticals Ltd ADR's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Telix Pharmaceuticals Ltd ADR, and counted as zero in the overall score.
Telix Pharmaceuticals Ltd ADR's revenue surged 55.6% year-over-year to $803.8M, reflecting rapid business expansion. This strong growth earns a score of 95/100.
Telix Pharmaceuticals Ltd ADR carries a low D/E ratio of 0.14, meaning only $0.14 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 78/100, indicating a strong balance sheet with room for future borrowing.
Telix Pharmaceuticals Ltd ADR's current ratio of 1.43 indicates adequate short-term liquidity, earning a score of 38/100. The company can meet its near-term obligations, though with limited headroom.
Telix Pharmaceuticals Ltd ADR's operations used $17.3M of cash, and capex of $25.7M added to the outflow, for a free cash flow shortfall of $43.0M. This results in a cash flow score of 26/100.
Not available for Telix Pharmaceuticals Ltd ADR, and counted as zero in the overall score.
Telix Pharmaceuticals Ltd ADR passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Telix Pharmaceuticals Ltd ADR reported a net loss of $7.1M while operations used $17.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Telix Pharmaceuticals Ltd ADR generated $803.8M in revenue in fiscal year 2025. This represents an increase of 55.6% from the prior year.
Telix Pharmaceuticals Ltd ADR reported -$7.1M in net income in fiscal year 2025. This represents a decrease of 121.2% from the prior year.
Telix Pharmaceuticals Ltd ADR earned -$0.02 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 121.6% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Telix Pharmaceuticals Ltd ADR recorded an outflow of $43.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 334.0% from the prior year.
Telix Pharmaceuticals Ltd ADR held $141.9M in cash against $56.5M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Telix Pharmaceuticals Ltd ADR's net profit margin was -0.9% in fiscal year 2025, showing the share of revenue converted to profit. This is down 7.4 percentage points from the prior year.
Telix Pharmaceuticals Ltd ADR's ROE was -1.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 11.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Telix Pharmaceuticals Ltd ADR invested $25.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 181.8% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
TLX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Revenue | $803.8M+55.6% | $516.6M+55.1% | $333.0M |
| Interest Expense | $3.6M+640.7% | $491K+16.1% | $423K |
| Income Tax | $1.9M-56.1% | $4.2M+362.1% | -$1.6M |
| Net Income | -$7.1M-121.2% | $33.7M+700.5% | $4.2M |
| EPS (Diluted) | -$0.02-121.6% | $0.10+650.8% | $0.01 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income.
TLX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Total Assets | $1.2B+23.8% | $940.4M+239.2% | $277.3M |
| Current Assets | $330.3M-42.1% | $570.1M+259.3% | $158.7M |
| Cash & Equivalents | $141.9M-67.8% | $440.0M+422.0% | $84.3M |
| Inventory | $37.1M+57.0% | $23.6M+85.4% | $12.7M |
| Accounts Receivable | $129.2M+48.6% | $86.9M+97.4% | $44.0M |
| Goodwill | $199.0M+198.8% | $66.6M-11.3% | $75.1M |
| Total Liabilities | $748.6M+27.4% | $587.4M+236.4% | $174.6M |
| Current Liabilities | $231.6M+12.9% | $205.1M+84.1% | $111.4M |
| Long-Term Debt | $56.5M+1021.3% | $5.0M-4.0% | $5.3M |
| Total Equity | $415.4M+17.7% | $352.9M+243.8% | $102.6M |
| Retained Earnings | -$154.5M-1.1% | -$152.9M+18.3% | -$187.1M |
TLX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Operating Cash Flow | -$17.3M-162.9% | $27.5M+92.6% | $14.3M |
| Capital Expenditures | $25.7M+181.8% | $9.1M+44.6% | $6.3M |
| Free Cash Flow | -$43.0M-334.0% | $18.4M+130.6% | $8.0M |
| Investing Cash Flow | -$285.9M-229.8% | -$86.7M-414.8% | -$16.8M |
| Financing Cash Flow | -$3.7M-100.9% | $416.8M+5777.7% | $7.1M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TLX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Net Margin | -0.9%-7.4pp | 6.5%+5.3pp | 1.3% |
| Return on Equity | -1.7%-11.3pp | 9.5%+5.4pp | 4.1% |
| Return on Assets | -0.6%-4.2pp | 3.6%+2.1pp | 1.5% |
| Current Ratio | 1.43-1.4x | 2.78+1.4x | 1.42 |
| Debt-to-Equity | 0.14+0.1x | 0.010.0x | 0.05 |
| FCF Margin | -5.3%-8.9pp | 3.6%+1.2pp | 2.4% |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin.
Similar Companies
Where Telix Pharmaceuticals Ltd ADR Ranks
Frequently Asked Questions
What is Telix Pharmaceuticals Ltd ADR's annual revenue?
Telix Pharmaceuticals Ltd ADR (TLX) reported $803.8M in total revenue for fiscal year 2025. This represents a 55.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Telix Pharmaceuticals Ltd ADR's revenue growing?
Telix Pharmaceuticals Ltd ADR (TLX) revenue grew by 55.6% year-over-year, from $516.6M to $803.8M in fiscal year 2025.
Is Telix Pharmaceuticals Ltd ADR profitable?
No, Telix Pharmaceuticals Ltd ADR (TLX) reported a net income of -$7.1M in fiscal year 2025, with a net profit margin of -0.9%.
How much debt does Telix Pharmaceuticals Ltd ADR have?
As of fiscal year 2025, Telix Pharmaceuticals Ltd ADR (TLX) had $141.9M in cash and equivalents against $56.5M in long-term debt.
What is Telix Pharmaceuticals Ltd ADR's net profit margin?
Telix Pharmaceuticals Ltd ADR (TLX) had a net profit margin of -0.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Telix Pharmaceuticals Ltd ADR's return on equity (ROE)?
Telix Pharmaceuticals Ltd ADR (TLX) has a return on equity of -1.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Telix Pharmaceuticals Ltd ADR's free cash flow?
Telix Pharmaceuticals Ltd ADR (TLX) recorded an outflow of $43.0M in free cash flow during fiscal year 2025. This represents a -334.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Telix Pharmaceuticals Ltd ADR's operating cash flow?
Telix Pharmaceuticals Ltd ADR (TLX) recorded an outflow of $17.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Telix Pharmaceuticals Ltd ADR's total assets?
Telix Pharmaceuticals Ltd ADR (TLX) had $1.2B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Telix Pharmaceuticals Ltd ADR's capital expenditures?
Telix Pharmaceuticals Ltd ADR (TLX) invested $25.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Telix Pharmaceuticals Ltd ADR's current ratio?
Telix Pharmaceuticals Ltd ADR (TLX) had a current ratio of 1.43 as of fiscal year 2025, which is considered adequate.
What is Telix Pharmaceuticals Ltd ADR's debt-to-equity ratio?
Telix Pharmaceuticals Ltd ADR (TLX) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Telix Pharmaceuticals Ltd ADR's return on assets (ROA)?
Telix Pharmaceuticals Ltd ADR (TLX) had a return on assets of -0.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Telix Pharmaceuticals Ltd ADR's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Telix Pharmaceuticals Ltd ADR (TLX) held $141.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $17.3M over that year. Dividing the one by the other, the reported balance equals about 98 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Telix Pharmaceuticals Ltd ADR's Piotroski F-Score?
Telix Pharmaceuticals Ltd ADR (TLX) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Telix Pharmaceuticals Ltd ADR's earnings high quality?
Telix Pharmaceuticals Ltd ADR (TLX) reported a net loss of $7.1M while operations used $17.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Telix Pharmaceuticals Ltd ADR?
Telix Pharmaceuticals Ltd ADR (TLX) scores 40 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.